ADMA icon

ADMA Biologics

21.31 USD
+0.08
0.38%
At close Apr 17, 4:00 PM EDT
After hours
21.31
+0.00
0.00%
1 day
0.38%
5 days
14.51%
1 month
14.14%
3 months
33.02%
6 months
32.20%
Year to date
18.59%
1 year
252.81%
5 years
692.19%
10 years
132.90%
 

About: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Employees: 685

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

179% more call options, than puts

Call options by funds: $43.8M | Put options by funds: $15.7M

32% more first-time investments, than exits

New positions opened: 75 | Existing positions closed: 57

22% more repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 102

4% more funds holding

Funds holding: 305 [Q3] → 318 (+13) [Q4]

3.3% less ownership

Funds ownership: 89.53% [Q3] → 86.23% (-3.3%) [Q4]

16% less capital invested

Capital invested by funds: $4.16B [Q3] → $3.5B (-$665M) [Q4]

29% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$25
17%
upside
Avg. target
$25
17%
upside
High target
$25
17%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Kristen Kluska
24% 1-year accuracy
24 / 101 met price target
17%upside
$25
Overweight
Reiterated
4 Mar 2025

Financial journalist opinion

Based on 14 articles about ADMA published over the past 30 days

Positive
Zacks Investment Research
2 days ago
Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $21.31, signifying a +0.38% move from its prior day's close.
Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know
Positive
Zacks Investment Research
3 days ago
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Negative
Zacks Investment Research
4 days ago
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Positive
Zacks Investment Research
4 days ago
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average
Adma Biologics (ADMA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA crossed above the 20-day moving average, suggesting a short-term bullish trend.
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average
Positive
Zacks Investment Research
4 days ago
Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?
Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?
Positive
Zacks Investment Research
4 days ago
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
Neutral
Zacks Investment Research
1 week ago
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Positive
Zacks Investment Research
1 week ago
Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?
Neutral
GlobeNewsWire
1 week ago
ADMA Biologics Statement on Tariffs
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain
ADMA Biologics Statement on Tariffs
Neutral
Zacks Investment Research
2 weeks ago
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
Charts implemented using Lightweight Charts™